Merck bolsters neurodegeneration program with Caraway acquisition

Companies agree deal worth up to $610m for preclinical pipeline targeting genetically defined neurodegenerative diseases.
Preclinical biopharma Caraway Therapeutics is to be acquired by pharma giant Merck in a deal worth up to $610 million. The companies revealed that a…Read More

Loyal gets promising FDA feedback on lifespan extension drug for dogs

Company founder says FDA has formally accepted that a drug can be developed and approved to extend lifespan.
In a blog post this week, Celine Halioua, the founder and CEO of dog longevity biotech Loyal, revealed that the company has received what it believes to be the…Read More

Biolexis lands $10m to advance metabolic drug program with longevity potential

Company is developing metabolic drug candidates targeting obesity, diabetes and human longevity.
AI-driven drug discovery company Biolexis Therapeutics has closed a $10 million Series A funding round, supporting its mission to advance metabolic drug development.…Read More

Interface Bio emerges with $3m to harness the microbiome against inflammation

AI-powered platform identifies bacterial natural products with the potential to modulate the immune system and reduce inflammation.
Biotech startup Interface Biosciences has secured $3 million in an oversubscribed seed funding round to advance its AI drug discovery…Read More